First International Bank of Israel (TASE: FIBI) one of Israel's major banking groups, today announced its results for ...
Launch and spacecraft vehicles in assembly at the Rocket Ranch, which supports ramped up capacity of carbon composite tanks ...
Vinci Compass Investments Ltd. (NASDAQ: VINP) ("Vinci Compass," "the Company," "we," "us," or "our"), the controlling ...
Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to ...
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ...
BOSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Zapata Quantum (OTCQB: ZPTA) ("Zapata," "Zapata Quantum" or the "Company"), a leader in quantum computing algorithm and application development, today ...
DALLAS, Aug. 12, 2026 /PRNewswire/ -- Brinker International, Inc. (NYSE: EAT) today announced its financial results for the fourth quarter and fiscal year ended June 24, 2026 and provided guidance for ...
New AI capability helps enterprises and insurers improve investigation quality while reaching a major enterprise security milestone through SOC 2 Type II attestation. ATLANTA, GA / ACCESS Newswire / ...
FIFA's digital experiences will be scaled using Glob.AI, Globant's AI-native tech services model, to create a seamless, personalized journey for millions of fans, with initial pilots indicating 20% ...
Industrial AI platform will connect primary emissions data to operating entities and trading desks in oil, gas and metals across Trafigura's global portfolio AMSTERDAM, Aug. 12, 2026 /PRNewswire/ -- ...
First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA study, validating internal commercial-ready manufacturing ...
Pharvaris N.V.: Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results